Giorgio Chirivì

Intesa San Paolo IMI

📍 Milan, Lombardy, Italy🔄 Updated September 2026💼 3 investments📅 21 years investing🗓 Last invested May 2016
Angel investor🌍 Italy
3
Total investments
0
Early stage
1
Mid stage
2
Late stage
21y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Member of the Board
May 2016
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
late stageBiotechnology
Member of the Board
Jan 2016
Biocell Center is a private laboratory that offers the cryopreservation of cells derived from the amniotic fluid, including amniotic fluid stem cells. Biocell Center was launched in Europe in 2006 by distinguished medical doctors following the discovery that amniotic stem cells possess unique characteristics compared to the cells derived from other sources, and has since built a laboratory and amniotic stem cell bank that focuses on the standardization and optimization of the cryopreservation protocol of the amniotic fluid and offers the option to preserve this important biological material to the individual families and to the medical centers. Biocell Center has been successfully collaborating with many leading hospitals, Ob/Gyn, maternal-fetal health groups and stem cell research laboratories worldwide, and currently has offices and laboratories in Italy, Switzerland and the US.
late stageBiotechnology
Member of the Board
Jan 2005
Axxam is a privately owned innovative Partner Research Organization (iPRO) providing, since its inception in 2001, excellent quality services in the early phases of drug discovery. Our capabilities and expertise include: - Molecular biology (cloning, gene expression analysis, protein expression, genomic engineering) - Assay development (cellular models, on recombinant cell lines as wells iPS cells, and biochemical systems) - Reagent provision (proteins and cell lines) - Off-the-shelf assays ready for profiling and High Throughput Screening - Fully automated High Throughput Screening – 384/1536 format (several read-outs available including radiometric) - Medium /high-throughput phenotypic screening - Electrophysiology (manual and automated, high-thoughput) - Access to the AXXDIV4.0 compound collection (around 325,000 compounds) and to the Symegold library (around 75,000 compounds) - Compound management - Hit follow-up programs - Safety and liability profiling - Innovative technologies for smarter assays These capabilities paired with our discovery mentality have allowed us to successfully execute: - Hit identification projects - Hit-to-lead projects - Lead optimization programs The headquarters of Axxam S.p.A. are located at OpenZone Campus in Bresso, a small city in the outskirt of Milan (Italy) that hosts also our biology laboratories while our medicinal chemistry laboratories are located at the Novartis Torre Campus in Torre Annunziata (Naples, Italy). Axxam Group has two screening facilities, one located at the headquarters in Italy and one in Constance (Germany), under Axxam GmbH, a subsidiary of Axxam S.p.A. that counts also a second business unit, called IMAX Discovery, focused on offering services to food and beverages, fragrance and cosmetic industries. Our clients are distributed around the globe and active in the Life Sciences as pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages.
Experience · 5 entries
All (5)
Investments (3)
Board (3)
2016
Member of the Board
May 2016
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
late stageBiotechnology
Member of the Board
Jan 2016
Biocell Center is a private laboratory that offers the cryopreservation of cells derived from the amniotic fluid, including amniotic fluid stem cells. Biocell Center was launched in Europe in 2006 by distinguished medical doctors following the discovery that amniotic stem cells possess unique characteristics compared to the cells derived from other sources, and has since built a laboratory and amniotic stem cell bank that focuses on the standardization and optimization of the cryopreservation protocol of the amniotic fluid and offers the option to preserve this important biological material to the individual families and to the medical centers. Biocell Center has been successfully collaborating with many leading hospitals, Ob/Gyn, maternal-fetal health groups and stem cell research laboratories worldwide, and currently has offices and laboratories in Italy, Switzerland and the US.
late stageBiotechnology
2013
Head M&A
2013
Since 5 August 2020 UBI Banca, established on 1 April 2007 from the merger between BPU Banca and Banca Lombarda, has been part of the Intesa Sanpaolo Group. UBI Banca was acquired by Intesa Sanpaolo. To see whats new, visit Intesa Sanpaolo.
late stageBanking
2005
Member of the Board
Jan 2005
Axxam is a privately owned innovative Partner Research Organization (iPRO) providing, since its inception in 2001, excellent quality services in the early phases of drug discovery. Our capabilities and expertise include: - Molecular biology (cloning, gene expression analysis, protein expression, genomic engineering) - Assay development (cellular models, on recombinant cell lines as wells iPS cells, and biochemical systems) - Reagent provision (proteins and cell lines) - Off-the-shelf assays ready for profiling and High Throughput Screening - Fully automated High Throughput Screening – 384/1536 format (several read-outs available including radiometric) - Medium /high-throughput phenotypic screening - Electrophysiology (manual and automated, high-thoughput) - Access to the AXXDIV4.0 compound collection (around 325,000 compounds) and to the Symegold library (around 75,000 compounds) - Compound management - Hit follow-up programs - Safety and liability profiling - Innovative technologies for smarter assays These capabilities paired with our discovery mentality have allowed us to successfully execute: - Hit identification projects - Hit-to-lead projects - Lead optimization programs The headquarters of Axxam S.p.A. are located at OpenZone Campus in Bresso, a small city in the outskirt of Milan (Italy) that hosts also our biology laboratories while our medicinal chemistry laboratories are located at the Novartis Torre Campus in Torre Annunziata (Naples, Italy). Axxam Group has two screening facilities, one located at the headquarters in Italy and one in Constance (Germany), under Axxam GmbH, a subsidiary of Axxam S.p.A. that counts also a second business unit, called IMAX Discovery, focused on offering services to food and beverages, fragrance and cosmetic industries. Our clients are distributed around the globe and active in the Life Sciences as pharmaceuticals, crop protection, animal health, cosmetics, fragrances, food and beverages.
2003
Centrobanca
Head Advisory - M&A Division
2003
Investment activity
2005–2016 · 3 investments
2005120162
Recent (last 2 years)Earlier